Progress in the development of volatile exhaled breath signatures of lung cancer

Annals of the American Thoracic Society

Volumn 12, Issue 5, 2015, Pages 752-757

  Mazzone, Peter J ^a   Wang, Xiao Feng ^a   Lim, Sung ^b   Jett, James ^c   Choi, Humberto ^a   Zhang, Qi ^a   Beukemann, Mary ^a   Seeley, Meredith ^a   Martino, Ray ^b   Rhodes, Paul ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Metabolomx   (United States)

^c DEPARTMENT OF MEDICINE   (United States)

Author keywords

Breath testing; Phenotypes; Volatile organic compounds

Indexed keywords

BIOLOGICAL MARKER; VOLATILE ORGANIC COMPOUND;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COLORIMETRIC SENSOR ARRAY; COLORIMETRY; COMORBIDITY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EXPIRED AIR; FAMILY HISTORY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL LUNG CARCINOMA; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG CANCER; LUNG NODULE; MALE; NON SMALL CELL LUNG CANCER; PHENOTYPE; RANDOM FOREST; SENSOR; SMALL CELL LUNG CANCER; SMOKING; SQUAMOUS CELL LUNG CARCINOMA; TUMOR BIOPSY; VOLATILE EXHALED BREATH; BIOPSY; BREATH ANALYSIS; EARLY DIAGNOSIS; EXHALATION; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES;

AGED; BIOMARKERS; BIOPSY; BREATH TESTS; COLORIMETRY; EARLY DIAGNOSIS; EXHALATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; VOLATILE ORGANIC COMPOUNDS;

EID: 84929610053     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201411-540OC     Document Type: Article

References (20)

1. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, et al.; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-967.
2. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363:1693-1703.
3. Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, Peek LJ, Allen J, Thorpe AJ, Hamilton-Fairley G, Parsy-Kowalska CB, et al. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol 2012;33:1319-1326.
4. Li XJ, Hayward C, Fong PY, Dominguez M, Hunsucker SW, Lee LW, McLean M, Law S, Butler H, Schirm M, et al. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci Transl Med 2013;5:207ra142.
5. Sozzi G, Boeri M, Rossi M, Verri C, Suatoni P, Bravi F, Roz L, Conte D, Grassi M, Sverzellati N, et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol 2014;32: 768-773.
6. Spira A, Beane JE, Shah V, Steiling K, Liu G, Schembri F, Gilman S, Dumas YM, Calner P, Sebastiani P, et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med 2007;13:361-366.
7. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GRS, Chandel NS. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 2010;107: 8788-8793.
8. Martin RCG, Li Y, Liu Q, Barker DF, Doll MA, Hein DW. Manganese superoxide dismutase expression as a function of genotype and lung cancer pathology. Cancer Invest 2010;28:813-819.
9. Park JY, Matsuo K, Suzuki T, Ito H, Hosono S, Kawase T, Watanabe M, Oze I, Hida T, Yatabe Y, et al. Impact of smoking on lung cancer risk is stronger in those with the homozygous aldehyde dehydrogenase 2 null allele in a Japanese population. Carcinogenesis 2010;31: 660-665.
10. An Z, Chen Y, Zhang R, Song Y, Sun J, He J, Bai J, Dong L, Zhan Q, Abliz Z. Integrated ionization approach for RRLC-MS/MS-based metabonomics: finding potential biomarkers for lung cancer. J Proteome Res 2010;9:4071-4081.
11. Sponring A, Filipiak W, Ager C, Schubert J, Miekisch W, Amann A, Troppmair J. Analysis of volatile organic compounds (VOCs) in the headspace of NCI-H1666 lung cancer cells. Cancer Biomark 2010;7: 153-161.
12. Poli D, Goldoni M, Corradi M, Acampa O, Carbognani P, Internullo E, Casalini A, Mutti A. Determination of aldehydes in exhaled breath of patients with lung cancer by means of on-fiber-derivatisation SPME-GC/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878: 2643-2651.
13. Peng G, Tisch U, Adams O, Hakim M, Shehada N, Broza YY, Billan S, Abdah-Bortnyak R, Kuten A, Haick H. Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nat Nanotechnol 2009;4:669-673.
14. Mazzone PJ, Hammel J, Dweik RA, Na J, Czich C, Laskowski D, Mekhail T. Lung cancer diagnosis by the analysis of exhaled breath with a colorimetric sensor array. Thorax 2007;62:565-568.
15. Mazzone PJ, Wang XF, Xu Y, Mekhail T, Beukemann MC, Na J, Kemling JW, Suslick KS, Sasidhar M. Exhaled breath analysis with a colorimetric sensor array for the identification and characterization of lung cancer. J Thorac Oncol 2012;7:137-142.
16. Mazzone PJ, Wang X, Rhodes P, Martino R, Lim S, Beukemann M, Seeley M, Choi H, Jett J. The analysis of volatile organic compound profiles in the breath as a biomarker of lung cancer [abstract]. Chest 2013;144(4-MeetingAbstracts):645A.
17. rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e93S-e120S.
18. Lim SH, Feng L, Kemling JW, Musto CJ, Suslick KS. An optoelectronic nose for the detection of toxic gases. Nat Chem 2009;1:562-567.
19. Haick H, Broza YY, Mochalski P, Ruzsanyi V, Amann A. Assessment, origin, and implementation of breath volatile cancer markers. Chem Soc Rev 2014;43:1423-1449.
20. Hakim M, Broza YY, Barash O, Peled N, Phillips M, Amann A, Haick H. Volatile organic compounds of lung cancer and possible biochemical pathways. Chem Rev 2012;112:5949-5966.